Welcome to our dedicated page for Moleculin Biotech SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Moleculin Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Moleculin Biotech's regulatory disclosures and financial reporting.
Moleculin Biotech, Inc. stockholders approved the issuance of up to 2,610,823 shares of common stock upon exercise of certain warrants issued on December 11, 2025. The warrant-related Nasdaq Proposal passed with 578,385 votes for, 68,176 against and 3,444 abstentions, with 546,307 broker non-votes.
Stockholders did not approve changing the company’s name to Moleculin Inc., because the vote did not reach the required majority of all outstanding shares, even though 1,124,921 voted for, 67,441 against and 3,950 abstained. They also approved a potential adjournment to solicit additional proxies if needed.
Moleculin Biotech, Inc. filed a current report to note that it is using a new corporate presentation for investors and other audiences. The presentation is posted on the company’s website and is included as Exhibit 99.1 to the report. The company specifies that this material is being furnished under a disclosure item for informational purposes and is not deemed filed under securities laws unless later specifically incorporated by reference.
Moleculin Biotech, Inc. filed a current report to furnish a press release about new safety information for its investigational drug Annamycin. The company states that an independent assessment confirmed no cardiotoxicity of Annamycin in 90 subjects, addressing an important safety consideration related to potential effects on the heart. The press release is included as Exhibit 99.1 and is furnished under Item 7.01, meaning it is provided for information purposes and is not treated as filed under securities law requirements.
Moleculin Biotech, Inc. filed a current report to furnish a press release dated January 12, 2026. The release states that the company is accelerating its outlook into 2026, with its first pivotal trial unblinding described as on track.
The press release also highlights global trial expansion and multiple clinical programs that are externally and investigator-initiated trial (IIT) funded. The information is furnished under a Regulation FD disclosure item and is not deemed filed under the federal securities laws unless later specifically incorporated by reference.
Moleculin Biotech, Inc. reported that it has regained compliance with Nasdaq’s continued listing standards. The company had previously been notified in May 2025 that it failed to meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and that it also did not meet the alternative tests for market value of listed securities or net income from continuing operations. In November 2025, Nasdaq staff issued a delisting determination, which Moleculin appealed to a hearing panel. On January 6, 2026, Nasdaq staff informed the panel that Moleculin is now in compliance with Listing Rule 5550(b)(1) and all other applicable continued listing standards, so the previously scheduled hearing has been cancelled and the company’s Nasdaq listing remains in place.
Moleculin Biotech, Inc. reports that it has issued a press release announcing positive results from a physician-sponsored Phase 1 clinical trial conducted at Emory University. The trial took place at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta and was led by pediatric oncologist Tobey MacDonald, MD, who identified STAT3 as critical to certain childhood brain tumors and directs the Pediatric Neuro-Oncology Program.
The company has attached the press release as Exhibit 99.1 to this report and incorporated it by reference, while specifying that the information is being furnished under the securities laws rather than filed.
Moleculin Biotech, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing of its common stock. The company had previously been notified on June 27, 2025 that its shares failed to meet the Nasdaq Listing Rule 5550(a)(2) requirement after trading below $1.00 per share for 30 consecutive business days.
Nasdaq’s Listing Qualifications Staff informed Moleculin on December 15, 2025 that the company is back in compliance because the closing bid price of its common stock was at or above $1.00 per share for 10 consecutive business days from December 1, 2025 through December 12, 2025. Nasdaq indicated that the company is now in compliance with the bid price rule and that the matter is closed.
Moleculin Biotech, Inc. (MBRX) furnished a new corporate presentation as an exhibit to a current report. The presentation, identified as Exhibit 99.1, is being used for the company’s corporate communications and is posted on its website. The company states that this material is being furnished under Regulation FD and will not be treated as "filed" for purposes of the Securities Exchange Act of 1934 or automatically incorporated into other SEC filings unless specifically referenced. This is primarily a disclosure and investor‑information update rather than an operational or financial event.
Moleculin Biotech, Inc. reported that Nasdaq has issued a determination to delist its common stock after the company failed to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity or specified alternative criteria.
Nasdaq previously gave the company until November 19, 2025 to regain compliance, but a letter dated November 20, 2025 states that the company remains non-compliant.
Unless Moleculin requests a hearing before a Nasdaq panel by November 28, 2025, its securities are scheduled to be delisted on December 2, 2025. The company intends to appeal this determination under Nasdaq’s procedures, and its common stock is expected to continue trading on The Nasdaq Capital Market under the symbol “MBRX” while the appeal is pending.
Moleculin Biotech (MBRX) filed a Form 4 for EVP & CFO Jonathan P. Foster reporting equity awards dated 11/12/2025. The filing lists a stock option for 600,000 shares at an exercise price of $0.49, expiring 11/12/2035, vesting in four equal annual installments beginning on the first anniversary. It also reports 400,000 performance-based RSUs that vest in 20% increments upon achievement of specified clinical milestones; 100% vest upon a change of control as defined in the 2024 Stock Plan. Following these transactions, derivative securities beneficially owned were 2,017,695, held directly.